Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 16/11/2018
SIETES contiene 92578 citas

 
 
 1 a 16 de 16 
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Bohula EA, Wiviott SD, McGuire DK, Inzucchi SE, Kuder J, Im K, Fanola CL, Qamar A, Brown C, Budaj A, García-Castillo A, Gupta M, Leiter LA, Weissman NJ, White HD, Patel T, Francis B, Miao W, Perdomo C, Dhadda S, Bonaca MP, Ruff CT, Keech AC, Smith SR, Sabatine MS, Scirica BM, CAMELLIA–TIMI 61 Steering Committee and Investigators. Cardiovascular safety of lorcaserin in overweight or obese patients. N Engl J Med 2018:26 de agosto. [Ref.ID 102827]
2.Enlace a cita original Cita con resumen
Dubreuil M, Louie-Gao Q, Peloquin CE, Choi HK, Zhang Y, Neogi T. Risk of myocardial infarction with use of selected non-steroidal anti-inflammatory drugs in patients with spondyloarthritis and osteoarthritis. Ann Rheum Dis 2018;77:agosto. [Ref.ID 102825]
3.Enlace a cita original Cita con resumen
Douros A, Dell'Aniello S, Yu OHY, Filion KB, Azoulay L, Suissa S. Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study. BMJ 2018;362:k2693. [Ref.ID 102821]
4.Enlace a cita original Cita con resumen
Chuang S-Y, Hsu P-F, Lin F-J, Huang Y-W, Wang G-Z, Chang W-C, Tsai H-J. Association between nonsteroidal anti-inflammatory drugs and atrial fibrillation among a middle-aged population: a nationwide population-based cohort. Br J Clin Pharmacol 2018;84:junio. [Ref.ID 102805]
5.Tiene citas relacionadas Cita con resumen
Wong AYS, Root A, Dogulas IJ, Chui CSL, Chan EW, Ghebremichael-Weldeselassie Y, Siu CW, Smeeth L, Wong ICK. Cardiovascular outcomes associated with use of clarithromycin: population based study. BMJ 2016;352:h6926. [Ref.ID 99982]
6.Tiene citas relacionadas Cita con resumen
Iyer G, Alexander GC. Cardiovascular risks associated with clarithromycin. BMJ 2016;352:i23. [Ref.ID 99980]
7. Cita con resumen
Bello AE, Holt RJ. Cardiovascular risk with non-steroidal anti-inflammatory drugs: clinical implications. Drug Saf 2014;37:897-902. [Ref.ID 98405]
8. Cita con resumen
Anónimo. Diclofenaco y riesgo cardiovascular: restricciones de uso.. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2013:17 de junio. [Ref.ID 97146]
9.Tiene citas relacionadas
Shaw P. ADHD medications and cardiovascular risk: some heartening news. JAMA 2011;306:2723-4. [Ref.ID 91840]
10.Tiene citas relacionadas Cita con resumen
Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, Cheetham C, Quinn VP, Dublin S, Boudreau DM, Andrade SE, Pawloski PA, Raebel MA, Smith DH, Achacoso N, Uratsu C, Go AS, Sidney S, Nguyen-Huynh MN. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA 2011;306:2673-83. [Ref.ID 91839]
11. Cita con resumen
Zuurman L, Ippel AE, Moin E, van Gerven JMA. Biomarkers for the effects of cannabis and THC in healthy volunteers. Br J Clin Pharmacol 2009;67:5-21. [Ref.ID 84981]
12. Cita con resumen
Day M. Don't blame it all on the bogey. BMJ 2007;334:1250-1. [Ref.ID 80354]
13. Cita con resumen
Tonks A. Short cuts. What's new in the other general journals. BMJ 2007;334:230-1. [Ref.ID 79096]
14.
Madea B, Grellner W. Long-term cardiovascular effects of anabolic steroids. Lancet 1998;352:33. [Ref.ID 39484]
15.
Matthews KA, Kuller LH, Wing RR, Meilahn EN, Plantinga P. Health prior to hormone use: Matthews et al. Reply to Grodstein. Am J Epidemiol 1996;143:983-4. [Ref.ID 28021]
Seleccionar todas
 
 1 a 16 de 16